Skip to main content

A Shoppers Drug Mart in downtown Toronto on Feb. 6 2014.

Fred Lum/The Globe and Mail

Loblaw Companies Ltd. said Friday it has closed its $12.4-billion cash-and-stock deal to buy Shoppers Drug Mart Corp., eight months after the takeover was first announced.

Under the agreement, which limited the amount of cash available, Shoppers Drug Mart shareholders who chose to receive cash will be paid $49.22 in cash and 0.2592 Loblaw shares for each share.

Shoppers Drug Mart shareholders who did not make a choice will receive $26.53 in cash and 0.7363 Loblaw shares for each share.

Story continues below advertisement

Loblaw received approval last week from the Competition Bureau for the takeover, subject to several conditions including the sale of 18 stores and nine Loblaw-run pharmacies to an independent operator.

The combined company has roughly 2,300 corporate, franchised and associate-owned stores across Canada and nearly 1,800 pharmacies.

Report an error
Tickers mentioned in this story
Unchecking box will stop auto data updates
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Discussion loading ...

Cannabis pro newsletter